author-photo

Nicola Steele

Beatson West of Scotland Cancer Centre

41

Papers

996

Citations

Citation Trend

Filter By

Papers (30) Sort By

Journal Conference Others

PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
1787P RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Case report: immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer

2019 International Journal of Neuroscience
Show All
- Source
- Cite
- Save
Citations (1)
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)